In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002432
Abstract: Background Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to… read more here.
Keywords: dcs; ipsc dcs; poorly immunogenic; antitumor ... See more keywords